Cargando…

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Detalles Bibliográficos
Autores principales:	Zhang, Qiang, Bykov, Vladimir J. N., Wiman, Klas G., Zawacka-Pankau, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893303/ https://www.ncbi.nlm.nih.gov/pubmed/31601779 http://dx.doi.org/10.1038/s41419-019-1997-z

Ejemplares similares

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Correction to: Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells
por: Sznarkowska, Alicja, et al.
Publicado: (2019)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

The Role of p53 Family in Cancer
por: Zawacka-Pankau, Joanna E.
Publicado: (2022)

Activation of TAp73 and inhibition of TrxR by Verteporfin for improved cancer therapy in TP53 mutant pancreatic tumors
por: Acedo, Pilar, et al.
Publicado: (2019)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

PRIMA-1(MET) Inhibits Growth of Mouse Tumors Carrying Mutant p53
por: Zache, Nicole, et al.
Publicado: (2008)

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis
por: Jiang, Liren, et al.
Publicado: (2020)

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing
por: Zawacka-Pankau, Joanna E.
Publicado: (2020)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors
por: Zhang, Meiqiongzi, et al.
Publicado: (2018)

The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer
por: Fregni, Matilde, et al.
Publicado: (2022)

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
por: Jiang, Liren, et al.
Publicado: (2019)

Mutant p53 targeting by the low molecular weight compound STIMA‐1
por: Zache, Nicole, et al.
Publicado: (2017)

Piperlongumine and p53-Reactivator APR-246 Selectively Induce Cell Death in HNSCC by Targeting GSTP1
por: Hang, Wei, et al.
Publicado: (2018)

p53 Forms Redox-Dependent Protein–Protein Interactions through Cysteine 277
por: Shi, Tao, et al.
Publicado: (2021)

Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells
por: Sznarkowska, Alicja, et al.
Publicado: (2018)

p53 as a hub in cellular redox regulation and therapeutic target in cancer
por: Eriksson, Sofi E, et al.
Publicado: (2019)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
por: Wang, Zilu, et al.
Publicado: (2023)

The Changes in the p53 Protein across the Animal Kingdom Point to Its Involvement in Longevity
por: Bartas, Martin, et al.
Publicado: (2021)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
por: Heldin, Angelos, et al.
Publicado: (2023)

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
por: Liang, Yayun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j3vj8lgfivrgam9lrsd8j39jvt